| Literature DB >> 28724973 |
Kasper Rømer Villumsen1, Erling Olaf Koppang2, Dennis Christensen3, Anders Miki Bojesen4.
Abstract
In an effort to reduce the frequency and severity of adverse reactions seen from the use of mineral oil adjuvants in salmonid fish, the effects of two alternative adjuvants were assessed, focusing on the induction of adverse effects as well as protection. Using rainbow trout (Oncorhynchus mykiss) as recipients, injection vaccines based on formalin-inactivated Aeromonas salmonicida subspecies salmonicida were formulated with CpG oligodeoxynucleotides, the liposomal cationic adjuvant formulation 01 (CAF01) or with Freund's incomplete adjuvant and administered intraperitoneally. Control groups of unvaccinated, Tris-buffered saline-injected or bacterin-injected individuals were included, and each group included in the study held a total number of 240 individuals. Subsequently, individuals from each group were examined for differences in Fulton's condition factor, macro- and microscopic pathological changes, as well as protection against experimental infection with A. salmonicida. While adverse effects were not eliminated, reductions in microscopic and macroscopic adverse effects, in particular, were seen for both the nucleotide- and liposome-based vaccine formulations. Furthermore, the induced protection appears similar to that of the benchmark formulation, thus introducing viable, potential alternative types of adjuvants for use in future fish vaccines.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28724973 PMCID: PMC5517504 DOI: 10.1038/s41598-017-06324-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Treatment specifications for each experimental group.
| Experimental Formulation: | Individuals: | Mix Ratio (v/v): | Content Per 100 µl Dose: | |
|---|---|---|---|---|
|
| Adjuvant | |||
| Naïve controls | 240 | — | — | — |
| TBS controls | 240 | — | — | TBS Only |
| Bacterin controls | 240 | — | 1 * 108 CFU | TBS Only |
| Bacterin + CpG ODN | 240 | 1:1 | 1 * 108 CFU | 0.6 nM CpG ODN in TBS |
| Bacterin + CAF01 | 240 | 1:1 | 1 * 108 CFU | 300 µg CAF01 in TBS |
| Bacterin + FIA | 240 | 1:1 | 1 * 108 CFU | 50 µl FIA |
The naïve controls did not receive any injection.
Individuals per aquarium during the experimental infection.
| Exp. group | Non-Infected Control | Infected Control | TBS Control | Bacterin Control | CpG-Formulation | CAF01-Formulation | FIA-Formulation |
|---|---|---|---|---|---|---|---|
| Aquarium 1 | 29 | 25 | 23 | 27 | 28 | 28 | 28 |
| Aquarium 2 | 27 | 30 | 33 | 28 | 28 | 27 | 28 |
Figure 1Fultons condition factor. Calculations and statistical methods are described in the materials and methods section. Values are presented as dot-plots with mean +/− standard deviation. Asterisks show statistically significant differences between groups and denote: *P < 0.05 and **P < 0.01. Condition factors obtained prior to vaccination are only for reference purposes. These were not included in the statistical comparisons.
Figure 2Results from post-mortem gross pathological scoring performed three (a–c) and ten (d–f) weeks post vaccination. Scoring and statistical methods are described in the materials and methods section. Scores are presented as dot-plots with median scores indicated. Asterisks show statistically significant differences between groups and denote: *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Figure 3Representative macroscopic observations made during post-mortem examination of vaccinated individuals at three and ten weeks post vaccination, shown on the left (a,c,e and g) and right hand side (b,d,f and h), respectively. Arrowheads indicate each observation. A) Focal pigmentation of intraperitoneal adipose tissue, bacterin group. (b) Diffuse pigmentation of abdominal viscera, CAF01 group. (c) Adhesion connecting adipose tissue to injection site, CAF01 group. (d) Adhesion connecting adipose tissue to injection site, CPG group. (e) Remnants of FIA emulsion in peritoneal cavity, FIA group. (f) Remnants of FIA emulsion in peritoneal cavity, FIA group. (g) Abdominal distension, CpG group. (h) Pigmentation near injection site, adhesion connecting viscera to injection site, remnants of FIA emulsion scattered in peritoneal cavity, FIA group. Scale bars measure 2 centimeters.
Figure 4Histological examination of sampled tissues. Unless otherwise stated, samples are HE-stained. (a) Melanomacrophage(s) in bulbus arteriosus, FIA group, three weeks post vaccination (3 wpv). Scalebar (sb)=200 µm. (b) Mott cell in anterior kidney, control group, 3 wpv. Sb = 100 µm. (c) Mott cell in liver, PAS stained, 10 wpv. Sb = 20 µm. (d) Hepatocellular vacuolization, 3 wpv. Sb = 100 µm. (e) Clear distinction between red (arrowhead) and white (arrow) splenic pulps with melanomacrophages in white pulp, CpG group, 10 wpv. Sb = 200 µm). (f) Eosinophilic granule cell in anterior kidney, FIA group, 10 wpv. Sb = 50 µm. (g) Melanomacrophage(s) in extraperitoneal adipose tissue, TBS group, 10 wpv. Sb = 200 µm. (h) Melanomacrophages in intraperitoneal adipose tissue, bacterin group, 3 wpv. Sb = 50 µm. (i) Fibrin deposits in intraperitoneal adipose tissue, MSB stain, bacterin group, 3 wpv. Sb = 100 µm. (j) Fibrin deposits in anterior kidney. Fibrin stain (arrow), as well as collagen and erythrocytes (arrowhead) are seen, MSB stain, CpG group, 3 wpv. Sb = 100 µm. (k) Inflammation in intraperitoneal adipose tissue, CAF01 group, 3 wpv. Sb = 200 µm. (l) Apparent liposomes in anterior kidney, CAF01 group, 3 wpv. Sb = 50 µm. (m) Higher magnification of L. Sb = 20 µm. (n) Hepatic necrosis, CAF01 group, 10 wpv. Sb = 200 µm. (o) Inflammation in spleen, CAF01 group, 10 wpv. Sb = 100 µm. (p) Inflammation in liver, FIA group, 3 wpv. Sb = 100 µm. (q) Fibrin deposits in anterior kidney, MSB stain, FIA group, 3 wpv. Sb = 50 µm. (r) Fibrin deposits in anterior kidney, MSB stain, FIA group, 10 wpv. Sb = 50 µm.
Figure 5Results from experimental infection experiment. Methodology, calculations and statistical methods are described in material and methods section, as well as in the results section. Each graph is indicated by a symbol at 28 days post infection. Symbols prior to this indicate censored individuals (see materials and methods section). Asterisks show statistically significant differences between groups and denote: *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Relative percent survival and hazard ratio results from the experimental infection.
| Group: | Hazard Ratio: | |||
|---|---|---|---|---|
| RPS: | Ratio: | 95% CI (Lower Limit) | 95% CI (Upper Limit) | |
| Bacterin Control | 81.1% | 0.16 | 0.10 | 0.44 |
| CpG | 68.8% | 0.28 | 0.14 | 0.62 |
| CAF01 | 59.1% | 0.36 | 0.18 | 0.74 |
| FIA | 59.3% | 0.34 | 0.17 | 0.70 |